Polo-like kinase 1 (Plk1) is an attractive target for the
development of anticancer agents
dueto its importance in regulating cell-cycle progression. Overexpression of Plk1 has been
detecte
d in avariety of cancers, an
d expression levels often correlate with poor prognosis. Despite high interest inPlk1-targete
d therapeutics, there is currently no structure publicly available to gui
de structure-base
d drug
design of specific inhibitors. We
determine
d the crystal structures of the T210V mutant of the kinase
domain of human Plk1 complexe
d with the nonhy
drolyzable ATP analogue a
denylylimi
do
diphosphate(AMPPNP) or the pyrrolo-pyrazole inhibitor PHA-680626 at 2.4 an
d 2.1 Å resolution, respectively.Plk1 a
dopts the typical kinase
domain fol
d an
d crystallize
d in a conformation resembling the activestate of other kinases. Comparison of the kinetic parameters
determine
d for the (unphosphorylate
d)wil
d-type enzyme, as well as the T210V an
d T210D mutants, shows that the mutations primarily affectthe
kcat of the reaction, with little change in the apparent
Km for the protein or nucleoti
de substrates (
kcat= 0.0094, 0.0376, an
d 0.0049 s
-1 an
d Km(ATP) = 3.2, 4.0, an
d 3.0
M for WT, T210D, an
d T210V,respectively). The structure highlights features of the active site that can be exploite
d to obtain Plk1-specific inhibitors with selectivity over other kinases an
d Plk isoforms. These inclu
de the presence of aphenylalanine at the bottom of the ATP pocket, combine
d with a cysteine (as oppose
d to the morecommonly foun
d leucine) in the roof of the bin
ding site, a pocket create
d by Leu132 in the hinge region,an
d a cluster of positively charge
d resi
dues in the solvent-expose
d area outsi
de of the a
denine pocketa
djacent to the hinge region.